Abstract
The long-term prognosis and outcomes of autoimmune pancreatitis (AIP) remain unclear. Because patients with AIP respond favorably to prednisolone (PSL) therapy in clinical, serological, imaging, and pathological settings [1–5], the disease was previously believed to be an acute condition that did not progress to an advanced stage of chronic pancreatitis. However, over the last decade, it has been revealed that some patients with AIP could progress to pancreatic stone formation, pancreatic atrophy, and/or irregular dilatation of the main pancreatic duct (MPD), which may raise new questions about whether AIP can progress to confirmed chronic pancreatitis or not.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58:1504–7.
Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol. 2010;45:471–7.
Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62:1771–6.
Song MH, Kim MH, Lee SK, Seo DW, Lee SS, Han J, et al. Regression of pancreatic fibrosis after steroid therapy in patients with autoimmune chronic pancreatitis. Pancreas. 2005;30:83–6.
Ko SB, Mizuno N, Yatabe Y, Yoshikawa T, Ishiguro H, Yamamoto A. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology. 2010;138:1988–96.
Takayama M, Hamano H, Ochi Y, Saegusa H, Komatsu K, Muraki T, et al. Recurrent attacks of autoimmune pancreatitis result in pancreatic stone formation. Am J Gastroenterol. 2004;99:932–7.
Kawa S, Hamano H, Ozaki Y, Ito T, Kodama R, Chou Y, et al. Long-term follow-up of autoimmune pancreatitis: characteristics of chronic disease and recurrence. Clin Gastroenterol Hepatol. 2009;7:S18–22.
Takuma K, Kamisawa T, Tabata T, Inaba Y, Egawa N, Igarashi Y. Short-term and long-term outcomes of autoimmune pancreatitis. Eur J Gastroenterol Hepatol. 2011;23:146–52.
Suzuki K, Itoh S, Nagasaka T, Ogawa H, Ota T, Naganawa S. CT findings in autoimmune pancreatitis: assessment using multiphase contrast-enhanced multisection CT. Clin Radiol. 2010;65:735–43.
Sah RP, Pannala R, Chari ST, Sugumar A, Clain JE, Levy MJ, et al. Prevalence, diagnosis, and profile of autoimmune pancreatitis presenting with features of acute or chronic pancreatitis. Clin Gastroenterol Hepatol. 2010;8:91–6.
Takada H, Nakazawa T, Ohara H, Ando T, Hayashi K, Naito I, et al. Role of osteopontin in calcification in autoimmune pancreatitis. Dig Dis Sci. 2009;54:793–801.
Nakazawa T, Ohara H, Sano H, Ando T, Imai H, Takada H, et al. Difficulty in diagnosing autoimmune pancreatitis by imaging findings. Gastrointest Endosc. 2007;65:99–108.
Nishino T, Toki F, Oyama H, Shimizu K, Shiratori K. Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. Intern Med. 2006;45:497–501.
Maire F, Le Baleur Y, Rebours V, Vullierme MP, Couvelard A, Voitot H, et al. Outcome of patients with type 1 or 2 autoimmune pancreatitis. Am J Gastroenterol. 2011;106:151–6.
Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–8.
Kawa S, Hamano H. Clinical features of autoimmune pancreatitis. J Gastroenterol. 2007;42 Suppl 18:9–14.
Muraki T, Hamano H, Ochi Y, Komatsu K, Komiyama Y, Arakura N, et al. Autoimmune pancreatitis and complement activation system. Pancreas. 2006;32:16–21.
Maruyama M, Arakura N, Ozaki Y, Watanabe T, Ito T, Yoneda S, et al. Risk factors for pancreatic stone formation in autoimmune pancreatitis over a long-term course. J Gastroenterol. 2012;47:553–60.
Hirano K, Tada M, Isayama H, Watanabe T, Saito T, Uchino R, et al. High alcohol consumption increases the risk of pancreatic stone formation and pancreatic atrophy in autoimmune pancreatitis. Pancreas. 2013;42(3):502–5.
Zhang X, Li W, Jiang L, Guo Y, Wang X. Clinical analysis of 36 cases of autoimmune pancreatitis in China. PLoS One. 2012;7:e44808.
Kawa S, Hamano H, Kiyosawa K. High serum IgG4 concentrations in patients with sclerosing pancreatitis. Reply. N Engl J Med. 2001;345:148.
Shimosegawa T, Kataoka K, Kamisawa T, Miyakawa H, Ohara H, Ito T, et al. The revised Japanese clinical diagnostic criteria for chronic pancreatitis. J Gastroenterol. 2010;45:584–91.
Maruyama M, Arakura N, Ozaki Y, Watanabe T, Ito T, Yoneda S, et al. Type 1 autoimmune pancreatitis can transform into chronic pancreatitis: a long-term follow-up study of 73 Japanese patients. Int J Rheumatol. 2013;2013:8.
Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Maruyama, M., Arakura, N., Kawa, S. (2015). Development to Chronic Pancreatitis. In: Kamisawa, T., Chung, J. (eds) Autoimmune Pancreatitis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55086-7_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-55086-7_25
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-55085-0
Online ISBN: 978-3-642-55086-7
eBook Packages: MedicineMedicine (R0)